2022
Estimating non-communicable disease treatment costs using probability-based cost estimation
Botha CR, Vermund SH. Estimating non-communicable disease treatment costs using probability-based cost estimation. Global Health Action 2022, 15: 2008627. PMID: 35147492, PMCID: PMC8843315, DOI: 10.1080/16549716.2021.2008627.Peer-Reviewed Original ResearchMeSH KeywordsHealth Care CostsHumansMortality, PrematureNoncommunicable DiseasesProbabilitySouth AfricaConceptsLevel dataCost estimationPublic financial resourcesDisease treatment costsSub-Saharan AfricaFuture costsHealthcare facility levelFinancial resourcesMiddle-income countriesCost estimatesInput variablesAvailability of dataResource allocationHealth sectorTotal costNon-communicable diseasesData-poor environmentsCostCountriesMean costPatient-level dataTreatment costsSouth AfricaTrend dataVariables
2013
Utilization of Cervical Cancer Screening Services and Trends in Screening Positivity Rates in a ‘Screen-And-Treat’ Program Integrated with HIV/AIDS Care in Zambia
Mwanahamuntu MH, Sahasrabuddhe VV, Blevins M, Kapambwe S, Shepherd BE, Chibwesha C, Pfaendler KS, Mkumba G, Vwalika B, Hicks ML, Vermund SH, Stringer JS, Parham GP. Utilization of Cervical Cancer Screening Services and Trends in Screening Positivity Rates in a ‘Screen-And-Treat’ Program Integrated with HIV/AIDS Care in Zambia. PLOS ONE 2013, 8: e74607. PMID: 24058599, PMCID: PMC3776830, DOI: 10.1371/journal.pone.0074607.Peer-Reviewed Original ResearchConceptsCervical cancer screening servicesCancer screening servicesHIV-seronegative womenHIV serostatusScreening servicesHIV/AIDS care programsCervical cancer prevention programsCervical cancer prevention servicesCervical cancer screening programsHIV/AIDS careHIV-seropositive womenCancer prevention servicesCancer prevention programsCancer screening programsAIDS care programsProportion of womenPatterns of utilizationHIV-seropositiveCervical cancerSaharan AfricaTest positivityPositivity rateAIDS careScreening programMultivariable modeling
2009
Early Neurologic Abnormalities Associated with Human T-Cell Lymphotropic Virus Type 1 Infection in a Cohort of Peruvian Children
Kendall EA, González E, Espinoza I, Tipismana M, Verdonck K, Clark D, Vermund SH, Gotuzzo E. Early Neurologic Abnormalities Associated with Human T-Cell Lymphotropic Virus Type 1 Infection in a Cohort of Peruvian Children. The Journal Of Pediatrics 2009, 155: 700-706. PMID: 19628219, PMCID: PMC2764792, DOI: 10.1016/j.jpeds.2009.05.027.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge DistributionAge of OnsetCase-Control StudiesChildChild, PreschoolCohort StudiesConfidence IntervalsFemaleHTLV-I InfectionsHuman T-lymphotropic virus 1HumansInfectious Disease Transmission, VerticalMaleNeurologic ExaminationOdds RatioParaparesisParaparesis, Tropical SpasticPeruPrevalenceProbabilityRisk AssessmentSeverity of Illness IndexSex DistributionSpinal Cord DiseasesTime FactorsUrination DisordersConceptsParesthesia/dysesthesiaHTLV-1 infectionNeurologic abnormalitiesInfective dermatitisHTLV-1Lumbar painHuman T-cell lymphotropic virus type 1 infectionMyelopathy/tropical spastic paraparesisHuman T-cell lymphotropic virus type 1Virus type 1 infectionPeruvian childrenAbnormal neurologic findingsEarly Neurologic AbnormalitiesLower extremity hyperreflexiaStandardized neurologic examinationType 1 infectionTropical spastic paraparesisWeakness/fatigueHTLV-1 statusVirus type 1Uninfected childrenNeurologic findingsNeurologic symptomsUrinary disturbanceNeurologic examination